A Study of the Pharmacodynamic Effects of Anti-Vascular Endothelial Growth

Status Completed

Clinical Trial Summary

The well-established role of vascular endothelial growth factor (VEGF) in carcinogenesis and tumor angiogenesis has led to the development of agents that target this pathway. Anti-VEGF agents the VEGF monoclonal antibody bevacizumab, and the small molecule VEGF receptor tyrosine kinase inhibitors. Angiogenic factors play a key role in the maintenance of lung integrity and normal endothelial function. Endothelial dysfunction has been implicated in hypertension, proteinuria and retinopathy. One of the major issues of anti-VEGF agents is its long-term toxicity especially taking into account the lack of adequate knowledge in this area and the possibility of prolonged periods of therapy in non-progressing patients. Hypertension and proteinuria are commonly seen in patients treated with anti-VEGF agents. In addition, the investigators have also observed in a relatively high frequency of pulmonary air-filled lesions in patients with malignancy in the lung treated with an anti-VEGF agent. Objectives of this exploratory study are to 1) determine the effect of anti-vascular endothelial growth factor (VEGF) on endothelial function 2) determine endothelial dysfunction as a marker of early response and as an indicator for the development of hypertension and proteinuria 3) characterize the effect of anti-VEGF therapy on the pulmonary function of patients with malignancy (primary or secondary) involving the lung in patients treated with anti-VEGF agents. Pharmacodynamic endpoints to be assessed are: blood pressure, brachial artery reactivity, retinal microvessels, microalbuminuria and proteinuria, pulmonary function, assess the effects of anti-VEGF therapy by assessing brachial artery reactivity, retinal vasculature and pulmonary function in a subset of patients receiving anti-VEGF therapy. The development of markers of endothelial dysfunction may result in the early identification of patients who are non-responders or develop toxicity from anti-VEGF treatment.

Clinical Trial Description

n/a

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00978926
Study type	Observational
Source	National University Hospital, Singapore
Contact
Status	Completed
Phase	N/A
Start date	September 2009

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01444404` - A Study of AMG 820 in Subjects With Advanced Solid Tumors	Phase 1
Completed	`NCT00428545` - Bevacizumab and Bortezomib in Patients With Advanced Malignancy	Phase 1
Completed	`NCT02743637` - A Dose Escalation Study of SDX-7320 in Patients With Advanced Refractory or Late-Stage Solid Tumors	Phase 1
Completed	`NCT01558817` - Changing the Paradigm of In-Hospital Cardiopulmonary Resuscitation With Informed Assent	N/A
Completed	`NCT01253707` - A Study of AMG 337 in Subjects With Advanced Solid Tumors	Phase 1
Completed	`NCT01723020` - A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma	Phase 1
Completed	`NCT00813384` - A Phase 1 Study of AMG 208 in Subjects With Advanced Solid Tumors	Phase 1
Completed	`NCT00974896` - QUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid Tumors	Phase 1
Completed	`NCT02110355` - A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma	Phase 1
Completed	`NCT02978482` - A Phase 1/2 Study of Durvalumab(MEDI4736) and Tremelimumab in Chinese Patients With Advanced Malignancies	Phase 1
Completed	`NCT00858377` - A Phase 1 First-in-Human Study Evaluating AMG 900 in Advanced Solid Tumors	Phase 1
Completed	`NCT04216082` - A Study of Anlotinib in Subjects With Advanced Malignancy	Phase 2
Terminated	`NCT02437916` - Safety Study of AMG 228 to Treat Solid Tumors	Phase 1
Terminated	`NCT01231347` - QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas	Phase 3
No longer available	`NCT01945164` - XL999 Administered Intravenously to a Subject With Advanced Malignancies	N/A
Completed	`NCT03875157` - Study of IBI318 in Participants With Advanced Malignancies	Phase 1
Completed	`NCT02016729` - A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia	Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

A Study of the Pharmacodynamic Effects of Anti-Vascular Endothelial Growth Factor Therapy in Patients With Advanced Malignancies

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms